Gilead: What the Heck is CAR-T, How Much is Too Much, and Other Kite Acquisition Questions
August 28, 2017 at 12:49 PM EDT
Gilead’s is paying almost $12 billion for Kite Pharma, a ringing endorsement for a new type of cancer drug known as CAR-T inhibitors. Will the bet pay off?
